The FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes.
The device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Senseonics’ implantable continuous glucose monitor appeared first on MassDevice.